# Pharmacokinetics and Tolerability of Extended-Release Clarithromycin

## Study Identification
- Title: Pharmacokinetics and Tolerability of Extended-Release Clarithromycin
- Authors: Guay DRP, Gustavson LE, Devcich KJ, et al.
- Publication: Clinical Therapeutics, Vol. 23, No. 4, 2001
- Study Type: Multiple pharmacokinetic studies and phase III clinical trials

## Antibiotic Classification
- Drug Class: Macrolide antibiotic
- Compound: Clarithromycin (semisynthetic macrolide)
- Formulations Studied: 
  * Extended-release (ER) tablets
  * Immediate-release (IR) tablets
  * Active metabolite: 14(R)-hydroxy-clarithromycin

## Research Objectives
1. Evaluate steady-state pharmacokinetic profiles of:
   - Clarithromycin ER (500mg tablets)
   - 14(R)-hydroxy-clarithromycin metabolite
2. Compare bioequivalence between ER and IR formulations
3. Assess food effect on ER formulation
4. Evaluate tolerability in phase III clinical trials

## Key Findings Summary

### Pharmacokinetic Outcomes
1. Bioequivalence demonstrated:
   - ER (with food) equivalent to IR based on AUC
   - Point estimate for relative bioavailability: 0.903 (parent compound)
   - Point estimate for metabolite: 1.041

2. Food Effect:
   - 30% lower bioavailability under fasting conditions
   - ER tablets should be taken with food

3. Extended Release Characteristics:
   - Significantly lower Cmax
   - Delayed Tmax
   - Lower concentration fluctuation
   - Supports once-daily dosing

### Clinical Outcomes
1. Tolerability:
   - Comparable overall adverse event rates between ER and IR
   - Lower severity of GI events with ER (p = 0.018)
   - Fewer discontinuations due to GI events with ER (p = 0.011)

2. Most Common Adverse Events:
   - Diarrhea (6% ER, 5% IR)
   - Abnormal taste (6% both formulations)
   - Nausea (3% ER, 5% IR)

# PHARMACOKINETIC ANALYSIS

## Analytical Methodology
- High-performance liquid chromatography with electrochemical detection
- Linear standard curves: 0.0156 to 11 mg/L
- Lower quantifiable limits: 0.02 mg/L (0.5-mL plasma sample)
- Intraday/interday coefficient variation: ±6%

## Study-Specific Pharmacokinetic Parameters

### Study 1: ER vs IR Bioequivalence (with food)

#### Parent Drug (Clarithromycin)
| Parameter | ER (2×500mg QD) | IR (500mg BID) | P-value |
|-----------|-----------------|----------------|----------|
| Cmax (mg/L) | 2.59 ± 0.71 | 3.51 ± 0.98 | <0.05 |
| Tmax (h) | 7.8 ± 4.0 | 2.1 ± 0.6 | <0.05 |
| Cmin (mg/L) | 0.76 ± 0.37 | 0.91 ± 0.39 | <0.05 |
| AUC24 (mg·h/L) | 42.1 ± 13.2 | 46.1 ± 13.8 | <0.05 |
| DFL | 1.08 ± 0.28 | 1.38 ± 0.25 | <0.05 |

#### Active Metabolite (14[R]-hydroxy-clarithromycin)
| Parameter | ER (2×500mg QD) | IR (500mg BID) | P-value |
|-----------|-----------------|----------------|----------|
| Cmax (mg/L) | 0.79 ± 0.17 | 0.82 ± 0.16 | NS |
| Tmax (h) | 8.7 ± 5.2 | 2.4 ± 1.7 | <0.05 |
| Cmin (mg/L) | 0.42 ± 0.13 | 0.42 ± 0.10 | NS |
| AUC24 (mg·h/L) | 15.1 ± 3.2 | 14.4 ± 2.9 | NS |
| DFL | 0.60 ± 0.23 | 0.67 ± 0.14 | <0.05 |

### Study 2: Food Effect Analysis

#### Parent Drug (Clarithromycin)
| Parameter | Fasting | Non-fasting | P-value |
|-----------|----------|-------------|----------|
| Cmax (mg/L) | 2.33 ± 0.70 | 3.91 ± 1.04 | <0.05 |
| Tmax (h) | 5.5 ± 3.1 | 5.6 ± 2.0 | NS |
| Cmin (mg/L) | 0.76 ± 0.44 | 0.80 ± 0.38 | NS |
| AUC24 (mg·h/L) | 35.9 ± 12.4 | 49.2 ± 10.5 | <0.05 |
| DFL | 1.13 ± 0.45 | 1.53 ± 0.44 | <0.05 |

#### Active Metabolite (14[R]-hydroxy-clarithromycin)
| Parameter | Fasting | Non-fasting | P-value |
|-----------|----------|-------------|----------|
| Cmax (mg/L) | 0.85 ± 0.27 | 0.85 ± 0.20 | NS |
| Tmax (h) | 4.9 ± 4.2 | 6.0 ± 4.0 | NS |
| Cmin (mg/L) | 0.40 ± 0.17 | 0.39 ± 0.12 | NS |
| AUC24 (mg·h/L) | 14.2 ± 3.7 | 14.6 ± 3.1 | NS |
| DFL | 0.78 ± 0.34 | 0.76 ± 0.27 | NS |

### Study 3: Lower Dose Comparison

#### Parent Drug (Clarithromycin)
| Parameter | ER (500mg QD) | IR (250mg BID) | P-value |
|-----------|---------------|----------------|----------|
| Cmax (mg/L) | 1.45 ± 0.43 | 1.94 ± 0.68 | <0.05 |
| Tmax (h) | 5.6 ± 2.1 | 2.4 ± 1.4 | <0.05 |
| Cmin (mg/L) | 0.31 ± 0.23 | 0.34 ± 0.15 | <0.05 |
| AUC24 (mg·h/L) | 20.4 ± 8.7 | 21.0 ± 6.9 | NS |
| DFL | 1.48 ± 0.54 | 1.84 ± 0.40 | <0.05 |

#### Active Metabolite (14[R]-hydroxy-clarithromycin)
| Parameter | ER (500mg QD) | IR (250mg BID) | P-value |
|-----------|---------------|----------------|----------|
| Cmax (mg/L) | 0.58 ± 0.17 | 0.60 ± 0.15 | NS |
| Tmax (h) | 6.0 ± 2.3 | 3.0 ± 2.3 | <0.05 |
| Cmin (mg/L) | 0.23 ± 0.13 | 0.24 ± 0.10 | NS |
| AUC24 (mg·h/L) | 9.5 ± 3.5 | 9.6 ± 2.8 | NS |
| DFL | 0.98 ± 0.39 | 0.95 ± 0.23 | NS |

## Key Pharmacokinetic Findings

### Bioavailability Assessment
1. Relative Bioavailability:
   - Study 1: ER/IR ratio = 0.903 (parent), 1.041 (metabolite)
   - Study 2: Fasting/Fed ratio = 0.701 (parent), 0.974 (metabolite)
   - Study 3: ER/IR ratio = 0.946 (parent), 0.969 (metabolite)

### Extended Release Characteristics
1. Consistent demonstration across all studies of:
   - Lower Cmax values
   - Delayed Tmax
   - Reduced concentration fluctuation
   - Maintained total exposure (AUC24)

### Food Effect Impact
1. Significant effect on parent drug:
   - 30% reduction in bioavailability when fasting
   - Higher peak concentrations with food
   - Similar Tmax regardless of food status

2. Minimal effect on metabolite:
   - Comparable exposure parameters
   - No significant differences in any PK parameters

### Dose-Proportionality Assessment
- Approximate dose proportionality observed between 500mg and 1000mg daily doses
- Linear pharmacokinetics within therapeutic range
- Consistent metabolite formation across dose ranges

## Statistical Considerations
- Noncompartmental analysis methods used
- 90% CIs for bioequivalence assessment
- Analysis of variance including sequence, period, and treatment effects
- Logarithmic transformation applied for all parameters except Tmax

# CLINICAL IMPLICATIONS

## Phase III Clinical Trial Demographics and Design

### Study Population Characteristics
| Parameter | ER Group (N=459) | IR Group (N=444) |
|-----------|------------------|------------------|
| Age (years) |  |  |
| - Mean ± SD | 50.5 ± 16.2 | 50.3 ± 17.2 |
| - Range | 13-86 | 15-89 |
| Gender, n (%) |  |  |
| - Female | 274 (59.7%) | 257 (57.9%) |
| - Male | 185 (40.3%) | 187 (42.1%) |
| Race, n (%) |  |  |
| - White | 396 (86.3%) | 389 (87.6%) |
| - Black | 35 (7.6%) | 26 (5.9%) |
| - Asian | 8 (1.7%) | 12 (2.7%) |
| - Other | 20 (4.4%) | 17 (3.8%) |
| Body Weight (kg) |  |  |
| - Mean ± SD | 81.4 ± 22.4 | 81.1 ± 20.1 |
| - Range | 42-195 | 44-158 |

### Trial Design Details
1. AMS Study (M97-667):
   - Duration: 14 days
   - ER dose: 1000mg (2×500mg) QD
   - IR dose: 500mg BID
   - N: 142 (ER), 141 (IR)

2. AECB Study (M97-756):
   - Duration: 7 days
   - ER dose: 1000mg (2×500mg) QD
   - IR dose: 500mg BID
   - N: 317 (ER), 303 (IR)

## Safety Profile Analysis

### Overall Adverse Event Rates
| Event Category | ER (N=459) | IR (N=444) | P-value |
|----------------|------------|------------|----------|
| Treatment-related AEs | 115 (25.1%) | 92 (20.7%) | NS |
| Severe AEs | 7 (1.5%) | 12 (2.7%) | NS |
| Discontinuations due to AEs | 11 (2.4%) | 18 (4.1%) | 0.004 |

### Common Adverse Events (≥3%)
| Event Type | ER (N=459) | IR (N=444) |
|------------|------------|------------|
| Diarrhea | 6% | 5% |
| Abnormal taste | 6% | 6% |
| Nausea | 3% | 5% |
| Abdominal pain | 2%* | 0% |
*P = 0.015 vs IR

### Severity Assessment
- GI Event Severity Score (1=mild, 2=moderate, 3=severe):
  * ER: 1.32 ± 0.51
  * IR: 1.58 ± 0.71
  * P = 0.018 favoring ER

## Subgroup Analyses

### Age-Stratified Analysis
- Three age strata evaluated:
  * ≤40 years (n=266)
  * 40-64 years (n=434)
  * ≥64 years (n=203)
- No significant differences between formulations in any age group

### Gender-Specific Findings
| Adverse Event | ER Females (n=274) | IR Females (n=257) | P-value |
|---------------|-------------------|-------------------|----------|
| Abdominal pain | 2.2% | 0% | 0.031 |
| Other AEs | No significant differences | | |

### Race-Specific Findings
| Adverse Event | ER White (n=396) | IR White (n=389) | P-value |
|---------------|------------------|------------------|----------|
| Abdominal pain | 1.5% | 0% | 0.031 |
| Dyspepsia | 0.3% | 2.1% | 0.020 |

## Clinical Laboratory Assessments
1. Serum Chemistry:
   - Potentially significant changes: 4 patients in each group
   - No clinically concerning patterns identified
   - No treatment discontinuations due to lab abnormalities

2. Vital Signs:
   - No clinically significant changes
   - No treatment-related patterns observed

## Therapeutic Recommendations

### Dosing Considerations
1. General Population:
   - ER: 1000mg once daily
   - Duration: 7 days (AECB) or 14 days (AMS)
   - Administration: With food

2. Special Populations:
   - No dose adjustments needed based on:
     * Age
     * Gender
     * Race
   - No specific contraindications identified

### Administration Guidelines
1. Timing:
   - Once-daily dosing
   - Consistent timing recommended
   - With food to optimize bioavailability

2. Compliance Considerations:
   - ≥80% compliance achieved in:
     * 93% of ER recipients
     * 91% of IR recipients
   - Simplified dosing schedule may improve adherence

### Monitoring Recommendations
1. Clinical Monitoring:
   - GI tolerability
   - Taste disturbances
   - Routine safety parameters

2. Laboratory Monitoring:
   - Baseline chemistry panel
   - Follow-up as clinically indicated
   - No specific monitoring requirements identified

## Therapeutic Advantages

### Pharmacokinetic Benefits
1. Once-Daily Dosing:
   - Simplified regimen
   - Potential for improved compliance
   - Maintained therapeutic exposure

2. Reduced Fluctuation:
   - More stable drug levels
   - Potentially improved tolerability
   - Maintained antimicrobial efficacy

### Clinical Benefits
1. Improved GI Tolerability:
   - Lower severity of GI events
   - Reduced discontinuation rates
   - Comparable overall safety profile

2. Compliance Benefits:
   - Simplified dosing schedule
   - Reduced pill burden
   - Potential for better adherence

## Limitations and Considerations

### Population Constraints
1. Study Population:
   - Limited diversity in racial composition
   - Mainly adult population
   - Healthy volunteers in PK studies

2. Clinical Settings:
   - Limited to AMS and AECB
   - No data for other infections
   - No severe infection data

### Clinical Practice Implications
1. Patient Selection:
   - Suitable for outpatient therapy
   - Appropriate for long-term therapy
   - Consider in poor compliance cases

2. Cost Considerations:
   - New formulation impacts
   - Once-daily versus twice-daily costs
   - Healthcare resource utilization

# APPENDIX A: TERMINOLOGY REFERENCE

## Pharmacokinetic Terms
| Term | Definition | Units |
|------|------------|-------|
| AUC24 | Area under the concentration-time curve (24h) | mg·h/L |
| Cmax | Peak plasma concentration | mg/L |
| Cmin | Trough plasma concentration | mg/L |
| Tmax | Time to peak concentration | h |
| DFL | Degree of fluctuation | ratio |
| F | Bioavailability | % |
| t1/2 | Half-life | h |
| CL/F | Apparent oral clearance | L/h |

## Formulation Abbreviations
| Abbreviation | Definition |
|--------------|------------|
| ER | Extended-release |
| IR | Immediate-release |
| QD | Once daily |
| BID | Twice daily |

## Clinical Terms
| Term | Definition |
|------|------------|
| AMS | Acute maxillary sinusitis |
| AECB | Acute exacerbation of chronic bronchitis |
| GI | Gastrointestinal |
| AE | Adverse event |

## Analytical Methods
| Term | Definition |
|------|------------|
| HPLC | High-performance liquid chromatography |
| CV | Coefficient of variation |
| LOQ | Limit of quantification |
| CI | Confidence interval |

# APPENDIX B: STATISTICAL METHODOLOGY

## Primary Statistical Methods

### Bioequivalence Analysis
1. Two One-Sided Tests Procedure:
   - 90% confidence intervals
   - Acceptance range: 0.80-1.25
   - Log-transformed parameters

2. ANOVA Model Components:
   - Sequence effects
   - Period effects
   - Treatment effects
   - Subject within sequence effects

### Safety Analysis Methods
1. Categorical Data:
   - Fisher's exact test
   - Chi-square test where appropriate
   - P-values reported to 3 decimal places

2. Continuous Data:
   - One-way ANOVA
   - Two-sided significance level: 0.05
   - Descriptive statistics (mean ± SD)

## Data Transformation Protocols
1. Pharmacokinetic Parameters:
   - Log-transformation for all parameters except Tmax
   - Natural logarithm base
   - Back-transformation for reporting

2. Adverse Events:
   - Severity scoring (1-3 scale)
   - Categorization by COSTART III
   - Relationship assessment criteria

## Statistical Software
- SAS/STAT® Version 6
- GLM procedure
- Descriptive statistics modules

# APPENDIX C: QUALITY METRICS AND VALIDATION

## Study Quality Parameters

### Pharmacokinetic Studies
1. Sample Analysis Quality:
   - Linear range: 0.0156-11 mg/L
   - LOQ: 0.02 mg/L
   - Intraday CV: ≤6%
   - Interday CV: ≤6%

2. Study Design Quality:
   - Randomization methods
   - Crossover design
   - Adequate washout periods
   - Sample size calculations

### Clinical Studies Quality
1. Protocol Compliance:
   - 93% ER group ≥80% adherent
   - 91% IR group ≥80% adherent
   - Documented dose timing
   - Food intake monitoring

2. Data Collection Quality:
   - Standardized AE reporting
   - Laboratory parameter monitoring
   - Vital signs documentation
   - Physical examination records

## Validation Methods

### Analytical Validation
1. HPLC Method:
   - Electrochemical detection
   - Internal standard use
   - System suitability criteria
   - Method validation protocol

2. Sample Handling:
   - Storage conditions
   - Stability data
   - Processing procedures
   - Chain of custody

### Clinical Validation
1. Adverse Event Validation:
   - Independent review
   - Severity assessment criteria
   - Causality determination
   - Documentation standards

2. Laboratory Validation:
   - Reference ranges
   - Quality control procedures
   - Calibration protocols
   - Result verification methods

# APPENDIX D: COMPLIANCE AND ETHICAL CONSIDERATIONS

## Regulatory Compliance

### Study Conduct
1. Protocol Adherence:
   - IRB approval obtained
   - Informed consent documented
   - Protocol modifications tracked
   - Deviation documentation

2. Data Management:
   - Quality control procedures
   - Data verification processes
   - Documentation standards
   - Archive protocols

### Ethical Standards
1. Subject Protection:
   - Written informed consent
   - Confidentiality maintenance
   - Risk minimization
   - Subject compensation

2. Clinical Practice Standards:
   - GCP compliance
   - Investigator qualifications
   - Facility requirements
   - Monitoring procedures

## Safety Monitoring

### Adverse Event Management
1. Reporting Requirements:
   - Immediate reporting criteria
   - Follow-up procedures
   - Documentation standards
   - Resolution tracking

2. Safety Assessment:
   - Regular monitoring
   - Risk evaluation
   - Intervention criteria
   - Follow-up protocols

### Study Termination Criteria
1. Individual Subject:
   - Safety thresholds
   - Withdrawal criteria
   - Follow-up requirements
   - Documentation needs

2. Study-Level:
   - Safety signals
   - Efficacy criteria
   - Quality thresholds
   - Administrative requirements